Hidoc Dr | Medical Learning App for Doctors

Today's Updates

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Published Date: 08 Oct 2026

Phase 2 VALIANT data show the anti-TSLP receptor antibody sharply reduced exacerbations in patients with high eosinophil counts.

Dupilumab's IL-4/IL-13 Blockade Drives Efficacy Edge in EVEREST Guy Brusselle, MD, PhD

Published Date: 08 Oct 2026

Guy Brusselle, MD, PhD, explains why broader cytokine blockade with dupilumab outpaced omalizumab, and why nonremitters in EVEREST still improved.

GLP-1/GIP Agonist KP405 Shows Biomarker Signal in Parkinson Disease Marco Meglio

Published Date: 08 Oct 2026

Exploratory extracellular vesicle biomarkers suggested KP405, a brain-penetrant GLP-1/GIP agonist, engaged insulin signaling and neuroinflammation pathways in a small phase 1 study.

12-Month Gluten-Free Diet Linked to Cognitive, Quality-of-Life Improvements in Parkinson Disease Louie Pasculli

Published Date: 08 Oct 2026

Late-breaking findings from MDS 2026 suggest a gluten-free diet may affect cognitive and quality-of-life measures in Parkinson disease, although no significant changes in motor function were observed.

From Cord Blood to Cannabinoids: 7 Agents to Watch in Cerebral Palsy Marco Meglio

Published Date: 08 Oct 2026

Seven investigational cerebral palsy therapies—from baby-tooth stem cells to cannabinoids and botulinum toxin—show mixed early results, highlighting key clinical trial milestones ahead.

Emerging Advances in Parkinson Disease Ahead of MDS 2026: Benjamin Walter, MD, MBA Benjamin L. Walter, MD, Louie Pasculli

Published Date: 08 Oct 2026

Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.

Clinical Forum Highlights Shifting Paradigm in NF1 Plexiform Neurofibroma Care Marco Meglio

Published Date: 08 Oct 2026

At a NeurologyLive Clinical Forum in Philadelphia, Jessica D. Schulte, MD, PhD, of NYU Grossman School of Medicine, discussed how earlier recognition and systemic therapy options are changing the treatment paradigm for patients with NF1-associated plexiform neurofibromas.

NeuroVoices: Kamalini Galvelis, MS, on Why Diverse Cohorts Matter in Replicating a GBA1 Intronic Risk Variant Isabella Ciccone, MPH, Kamalini Galvelis, MS

Published Date: 08 Oct 2026

The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of African ancestry.

Oral D1/D2 Agonist Lu AF28996 Increases Good ON-Time in Phase 1b Advanced PD Study, Phase 2 DARE2 Trial Begins Isabella Ciccone, MPH

Published Date: 08 Oct 2026

Investigational oral dopamine agonist prodrug boosts good ON-time, cuts OFF-time and dyskinesia, and reduces levodopa in advanced Parkinson disease, as phase 2 begins.

8 Endocrinology Headlines You Missed in Q3 2026

Published Date: 08 Oct 2026

8 Endocrinology Headlines You Missed in Q3 2026

Knowledge Hub

Oncology

Case-Based Learning: Cancer-Associated Thrombosis During Noncytotoxic Therapy

Review of cancer-associated thrombosis during noncytotoxic therapy, highlighting mechanisms, management, and clinical guidance for healthcare professionals.

Oncology

Pharmacokinetic Optimization of Combination Cancer Therapy

Comprehensive review of strategies for pharmacokinetic optimization in combination cancer therapy for improved clinical outcomes.

Oncology

Monitoring Delayed Toxicity of Antibody Therapies

Comprehensive review of delayed toxicity monitoring in antibody therapies for clinicians.

Oncology

Personalized Oncolytic Virus Combinations: Current Evidence and Clinical Implications

A comprehensive review of personalized oncolytic virus combinations in oncology, highlighting mechanisms, clinical evidence, and practical guidance.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Dupilumab's IL-4/IL-13 Blockade Drives Efficacy Edge in EVEREST Guy Brusselle, MD, PhD

GLP-1/GIP Agonist KP405 Shows Biomarker Signal in Parkinson Disease Marco Meglio

12-Month Gluten-Free Diet Linked to Cognitive, Quality-of-Life Improvements in Parkinson Disease Louie Pasculli

From Cord Blood to Cannabinoids: 7 Agents to Watch in Cerebral Palsy Marco Meglio

Emerging Advances in Parkinson Disease Ahead of MDS 2026: Benjamin Walter, MD, MBA Benjamin L. Walter, MD, Louie Pasculli

Clinical Forum Highlights Shifting Paradigm in NF1 Plexiform Neurofibroma Care Marco Meglio

NeuroVoices: Kamalini Galvelis, MS, on Why Diverse Cohorts Matter in Replicating a GBA1 Intronic Risk Variant Isabella Ciccone, MPH, Kamalini Galvelis, MS

Oral D1/D2 Agonist Lu AF28996 Increases Good ON-Time in Phase 1b Advanced PD Study, Phase 2 DARE2 Trial Begins Isabella Ciccone, MPH

8 Endocrinology Headlines You Missed in Q3 2026

Knowledge Hub

Case-Based Learning: Cancer-Associated Thrombosis During Noncytotoxic Therapy

Pharmacokinetic Optimization of Combination Cancer Therapy

Monitoring Delayed Toxicity of Antibody Therapies

Personalized Oncolytic Virus Combinations: Current Evidence and Clinical Implications

Population Surveillance of Environmental Cancer Risk Clusters

Community Strategies for Improving Cancer Prevention Literacy

Mechanisms of Tumor Cell Plasticity During Metastatic Spread

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Dupilumab's IL-4/IL-13 Blockade Drives Efficacy Edge in EVEREST Guy Brusselle, MD, PhD

GLP-1/GIP Agonist KP405 Shows Biomarker Signal in Parkinson Disease Marco Meglio

12-Month Gluten-Free Diet Linked to Cognitive, Quality-of-Life Improvements in Parkinson Disease Louie Pasculli

From Cord Blood to Cannabinoids: 7 Agents to Watch in Cerebral Palsy Marco Meglio

Emerging Advances in Parkinson Disease Ahead of MDS 2026: Benjamin Walter, MD, MBA Benjamin L. Walter, MD, Louie Pasculli

Clinical Forum Highlights Shifting Paradigm in NF1 Plexiform Neurofibroma Care Marco Meglio

NeuroVoices: Kamalini Galvelis, MS, on Why Diverse Cohorts Matter in Replicating a GBA1 Intronic Risk Variant Isabella Ciccone, MPH, Kamalini Galvelis, MS

Oral D1/D2 Agonist Lu AF28996 Increases Good ON-Time in Phase 1b Advanced PD Study, Phase 2 DARE2 Trial Begins Isabella Ciccone, MPH

8 Endocrinology Headlines You Missed in Q3 2026

Knowledge Hub

Case-Based Learning: Cancer-Associated Thrombosis During Noncytotoxic Therapy

Pharmacokinetic Optimization of Combination Cancer Therapy

Monitoring Delayed Toxicity of Antibody Therapies

Personalized Oncolytic Virus Combinations: Current Evidence and Clinical Implications

Population Surveillance of Environmental Cancer Risk Clusters

Community Strategies for Improving Cancer Prevention Literacy

Mechanisms of Tumor Cell Plasticity During Metastatic Spread

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views